Amphion Innovations plc is a principal investment firm specializing in both public and private early stage investments and spun out of universities and corporations. It does not invest in “speculative” technologies requiring long development timeframes or excessive capital investment. It invests in the medical, life sciences, and technology sectors with defensible core intellectual property, know-how and growth potential in very large markets of at least $1 billion in size together with corporations, governments, universities, and entrepreneurs. The firm typically invests in companies with broad-based, proprietary, platform technologies in the areas of pharmacogenomics, proteomics, nutriceut...
330 Madison Avenue
New York, NY 10017
Founded in 1984
Amphion Innovations plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended 30 June 2015
Sep 3 15
Amphion Innovations plc announced unaudited consolidated earnings results for the six months ended 30 June 2015. Revenue was $267,601 compared to $240,000 a year ago. Revenue remained at about the same level as last year and below prior periods mainly due to the absence of licensing income from DataTern, the wholly-owned Amphion subsidiary. Operating loss was $1,254,554 compared to $1,769,275 a year ago. Profit before tax was $33,151,642 compared to loss of $8,104,687 a year ago. Profit for the period was $33,151,642 or $0.15 per diluted share compared to loss of $8,104,750 or $0.06 per diluted share a year ago. Net cash used in operating activities was $1,844,267 compared to $2,428,337 a year ago.
Amphion Innovations Plc, Annual General Meeting, Aug 07, 2015
Jul 1 15
Amphion Innovations Plc, Annual General Meeting, Aug 07, 2015.
Amphion Innovations Plc Announces Audited Consolidated and Company Earnings Results for the Year Ended December 31, 2014
Jun 23 15
Amphion Innovations Plc announced audited consolidated and company earnings results for the year ended December 31, 2014. For the year, on consolidated basis, the company announced revenue of $484,700 compared to $1,016,990 a year ago. Operating loss was $3,009,651 compared to $2,576,745 a year ago. Loss before tax was $12,589,279 compared to $6,385,416 a year ago. Loss was $12,589,703 or $0.09 per basic and diluted share compared to $6,382,194 or $0.04 per basic and diluted share a year ago. Net cash used in operating activities was $1,976,585 compared to $1,701,969 a year ago. Purchases of investments were $286,259 compared to $204,959 a year ago.
For the year, on company only basis, the company announced operating loss was $1,121,478 compared to $1,099,965 a year ago. Loss before tax was $10,880,335 compared to $4,927,980 a year ago. Loss was $10,880,335 compared to $4,927,980 a year ago. Net cash used in operating activities was $3,110,973 compared to $650,844 a year ago. Purchases of investments were $286,259 compared to $204,959 a year ago.